Suppression of NRAS-mutant melanoma growth with NRAS-targeting Antisense Oligonucleotide treatment reveals therapeutically relevant kinase co-dependencies
Abstract Background Melanoma is an aggressive form of skin cancer, and patients with NRAS-mutant melanoma face limited treatment options due to the lack of direct NRAS inhibitors. This study explores the utilization of antisense oligonucleotides (ASOs) to directly target NRAS-mRNA for therapeutic ap...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-06-01
|
| Series: | Communications Medicine |
| Online Access: | https://doi.org/10.1038/s43856-025-00932-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850136303109144576 |
|---|---|
| author | Valentin Feichtenschlager Yixuan James Zheng Tiange Qu Dasha Hohlova Ciara Callanan Linan Chen Christopher Chen Wilson Ho Albert Lee Yeonjoo Hwang Arowyn Courtright Thy Nguyen Olivia Marsicovetere Denise P. Muñoz Klemens Rappersberger Jean-Philippe Coppe Susana Ortiz-Urda |
| author_facet | Valentin Feichtenschlager Yixuan James Zheng Tiange Qu Dasha Hohlova Ciara Callanan Linan Chen Christopher Chen Wilson Ho Albert Lee Yeonjoo Hwang Arowyn Courtright Thy Nguyen Olivia Marsicovetere Denise P. Muñoz Klemens Rappersberger Jean-Philippe Coppe Susana Ortiz-Urda |
| author_sort | Valentin Feichtenschlager |
| collection | DOAJ |
| description | Abstract Background Melanoma is an aggressive form of skin cancer, and patients with NRAS-mutant melanoma face limited treatment options due to the lack of direct NRAS inhibitors. This study explores the utilization of antisense oligonucleotides (ASOs) to directly target NRAS-mRNA for therapeutic approaches. Methods We designed and tested NRAS-mRNA-targeting ASOs. Experiments in melanoma cell lines and mouse models assessed effects on cell survival, apoptosis, and tumor growth. A kinase activity profiling platform identified therapeutically exploitable pathways influenced by NRAS suppression. Results Our research suggests that ASOs do not need to target the mutated NRAS segment to be effective. ASOs designed for the non-mutated NRAS sequence eliminate NRAS-dependent melanoma cells while sparing NRAS wild-type cells. They act independently of subcellular target localization, reduce NRAS-mRNA levels, inhibit MAPK signaling, induce apoptosis, and suppress melanoma growth in vitro and in vivo. Outcomes of high-throughput kinase activity mapping (HT-KAM) indicate a significant dependency between NRAS-mRNA expression and the activity of MEK1, FGFR2, and CDK4 kinases. Co-targeting these kinases enhances the antiproliferative effect of NRAS ASOs, showing synergy. Conclusions These findings highlight antisense oligonucleotides as a promising therapeutic approach for NRAS-mutant melanoma. By effectively blocking NRAS-mRNA, this strategy overcomes challenges posed by the absence of a direct small molecule inhibitor for NRAS, and may offer new treatment options for patients. |
| format | Article |
| id | doaj-art-86e7db8f2c9648dd937cea845cf7b403 |
| institution | OA Journals |
| issn | 2730-664X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Communications Medicine |
| spelling | doaj-art-86e7db8f2c9648dd937cea845cf7b4032025-08-20T02:31:09ZengNature PortfolioCommunications Medicine2730-664X2025-06-015111610.1038/s43856-025-00932-5Suppression of NRAS-mutant melanoma growth with NRAS-targeting Antisense Oligonucleotide treatment reveals therapeutically relevant kinase co-dependenciesValentin Feichtenschlager0Yixuan James Zheng1Tiange Qu2Dasha Hohlova3Ciara Callanan4Linan Chen5Christopher Chen6Wilson Ho7Albert Lee8Yeonjoo Hwang9Arowyn Courtright10Thy Nguyen11Olivia Marsicovetere12Denise P. Muñoz13Klemens Rappersberger14Jean-Philippe Coppe15Susana Ortiz-Urda16Department of Dermatology, Mt Zion Cancer Research Center, University of California San FranciscoDepartment of Dermatology, Mt Zion Cancer Research Center, University of California San FranciscoDepartment of Orofacial Science, Health Science West, University of California San Francisco School of DentistryDepartment of Dermatology, Mt Zion Cancer Research Center, University of California San FranciscoDepartment of Dermatology, Mt Zion Cancer Research Center, University of California San FranciscoDepartment of Dermatology, Mt Zion Cancer Research Center, University of California San FranciscoDepartment of Dermatology, Mt Zion Cancer Research Center, University of California San FranciscoDepartment of Dermatology, Mt Zion Cancer Research Center, University of California San FranciscoDepartment of Dermatology, Mt Zion Cancer Research Center, University of California San FranciscoDepartment of Hematology-Oncology, Helen Diller Family Comprehensive Cancer Center, University of California San FranciscoDepartment of Dermatology, Mt Zion Cancer Research Center, University of California San FranciscoDepartment of Dermatology, Mt Zion Cancer Research Center, University of California San FranciscoDepartment of Dermatology, Mt Zion Cancer Research Center, University of California San FranciscoDepartment of Hematology-Oncology, Helen Diller Family Comprehensive Cancer Center, University of California San FranciscoDepartment of Dermatology, Clinic Landstrasse Vienna, Academic Teaching Hospital, Medical University ViennaDepartment of Radiation Oncology, Helen Diller Family Comprehensive Cancer Center, University of California San FranciscoDepartment of Dermatology, Mt Zion Cancer Research Center, University of California San FranciscoAbstract Background Melanoma is an aggressive form of skin cancer, and patients with NRAS-mutant melanoma face limited treatment options due to the lack of direct NRAS inhibitors. This study explores the utilization of antisense oligonucleotides (ASOs) to directly target NRAS-mRNA for therapeutic approaches. Methods We designed and tested NRAS-mRNA-targeting ASOs. Experiments in melanoma cell lines and mouse models assessed effects on cell survival, apoptosis, and tumor growth. A kinase activity profiling platform identified therapeutically exploitable pathways influenced by NRAS suppression. Results Our research suggests that ASOs do not need to target the mutated NRAS segment to be effective. ASOs designed for the non-mutated NRAS sequence eliminate NRAS-dependent melanoma cells while sparing NRAS wild-type cells. They act independently of subcellular target localization, reduce NRAS-mRNA levels, inhibit MAPK signaling, induce apoptosis, and suppress melanoma growth in vitro and in vivo. Outcomes of high-throughput kinase activity mapping (HT-KAM) indicate a significant dependency between NRAS-mRNA expression and the activity of MEK1, FGFR2, and CDK4 kinases. Co-targeting these kinases enhances the antiproliferative effect of NRAS ASOs, showing synergy. Conclusions These findings highlight antisense oligonucleotides as a promising therapeutic approach for NRAS-mutant melanoma. By effectively blocking NRAS-mRNA, this strategy overcomes challenges posed by the absence of a direct small molecule inhibitor for NRAS, and may offer new treatment options for patients.https://doi.org/10.1038/s43856-025-00932-5 |
| spellingShingle | Valentin Feichtenschlager Yixuan James Zheng Tiange Qu Dasha Hohlova Ciara Callanan Linan Chen Christopher Chen Wilson Ho Albert Lee Yeonjoo Hwang Arowyn Courtright Thy Nguyen Olivia Marsicovetere Denise P. Muñoz Klemens Rappersberger Jean-Philippe Coppe Susana Ortiz-Urda Suppression of NRAS-mutant melanoma growth with NRAS-targeting Antisense Oligonucleotide treatment reveals therapeutically relevant kinase co-dependencies Communications Medicine |
| title | Suppression of NRAS-mutant melanoma growth with NRAS-targeting Antisense Oligonucleotide treatment reveals therapeutically relevant kinase co-dependencies |
| title_full | Suppression of NRAS-mutant melanoma growth with NRAS-targeting Antisense Oligonucleotide treatment reveals therapeutically relevant kinase co-dependencies |
| title_fullStr | Suppression of NRAS-mutant melanoma growth with NRAS-targeting Antisense Oligonucleotide treatment reveals therapeutically relevant kinase co-dependencies |
| title_full_unstemmed | Suppression of NRAS-mutant melanoma growth with NRAS-targeting Antisense Oligonucleotide treatment reveals therapeutically relevant kinase co-dependencies |
| title_short | Suppression of NRAS-mutant melanoma growth with NRAS-targeting Antisense Oligonucleotide treatment reveals therapeutically relevant kinase co-dependencies |
| title_sort | suppression of nras mutant melanoma growth with nras targeting antisense oligonucleotide treatment reveals therapeutically relevant kinase co dependencies |
| url | https://doi.org/10.1038/s43856-025-00932-5 |
| work_keys_str_mv | AT valentinfeichtenschlager suppressionofnrasmutantmelanomagrowthwithnrastargetingantisenseoligonucleotidetreatmentrevealstherapeuticallyrelevantkinasecodependencies AT yixuanjameszheng suppressionofnrasmutantmelanomagrowthwithnrastargetingantisenseoligonucleotidetreatmentrevealstherapeuticallyrelevantkinasecodependencies AT tiangequ suppressionofnrasmutantmelanomagrowthwithnrastargetingantisenseoligonucleotidetreatmentrevealstherapeuticallyrelevantkinasecodependencies AT dashahohlova suppressionofnrasmutantmelanomagrowthwithnrastargetingantisenseoligonucleotidetreatmentrevealstherapeuticallyrelevantkinasecodependencies AT ciaracallanan suppressionofnrasmutantmelanomagrowthwithnrastargetingantisenseoligonucleotidetreatmentrevealstherapeuticallyrelevantkinasecodependencies AT linanchen suppressionofnrasmutantmelanomagrowthwithnrastargetingantisenseoligonucleotidetreatmentrevealstherapeuticallyrelevantkinasecodependencies AT christopherchen suppressionofnrasmutantmelanomagrowthwithnrastargetingantisenseoligonucleotidetreatmentrevealstherapeuticallyrelevantkinasecodependencies AT wilsonho suppressionofnrasmutantmelanomagrowthwithnrastargetingantisenseoligonucleotidetreatmentrevealstherapeuticallyrelevantkinasecodependencies AT albertlee suppressionofnrasmutantmelanomagrowthwithnrastargetingantisenseoligonucleotidetreatmentrevealstherapeuticallyrelevantkinasecodependencies AT yeonjoohwang suppressionofnrasmutantmelanomagrowthwithnrastargetingantisenseoligonucleotidetreatmentrevealstherapeuticallyrelevantkinasecodependencies AT arowyncourtright suppressionofnrasmutantmelanomagrowthwithnrastargetingantisenseoligonucleotidetreatmentrevealstherapeuticallyrelevantkinasecodependencies AT thynguyen suppressionofnrasmutantmelanomagrowthwithnrastargetingantisenseoligonucleotidetreatmentrevealstherapeuticallyrelevantkinasecodependencies AT oliviamarsicovetere suppressionofnrasmutantmelanomagrowthwithnrastargetingantisenseoligonucleotidetreatmentrevealstherapeuticallyrelevantkinasecodependencies AT denisepmunoz suppressionofnrasmutantmelanomagrowthwithnrastargetingantisenseoligonucleotidetreatmentrevealstherapeuticallyrelevantkinasecodependencies AT klemensrappersberger suppressionofnrasmutantmelanomagrowthwithnrastargetingantisenseoligonucleotidetreatmentrevealstherapeuticallyrelevantkinasecodependencies AT jeanphilippecoppe suppressionofnrasmutantmelanomagrowthwithnrastargetingantisenseoligonucleotidetreatmentrevealstherapeuticallyrelevantkinasecodependencies AT susanaortizurda suppressionofnrasmutantmelanomagrowthwithnrastargetingantisenseoligonucleotidetreatmentrevealstherapeuticallyrelevantkinasecodependencies |